» Articles » PMID: 33347473

Rapid Identification of Anti-idiotypic MAbs with High Affinity and Diverse Epitopes by Rabbit Single B-cell Sorting-culture and Cloning Technology

Overview
Journal PLoS One
Date 2020 Dec 21
PMID 33347473
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The proactive generation of anti-idiotypic antibodies (anti-IDs) against therapeutic antibodies with desirable properties is an important step in pre-clinical and clinical assay development supporting their bioanalytical programs. Here, we describe a robust platform to generate anti-IDs using rabbit single B cell sorting-culture and cloning technology by immunizing rabbits with therapeutic drug Fab fragment and sorting complementarity determining regions (CDRs) specific B cells using designed framework control as a negative gate to exclude non-CDRs-specific B cells. The supernatants of cultured B cells were subsequently screened for binding to drug-molecule by enzyme-linked immunosorbent assay and the positive hits of B cell lysates were selected for cloning of their immunoglobulin G (IgG) variable regions. The recombinant monoclonal anti-IDs generated with this method have high affinity and specificity with broad epitope coverage and different types. The recombinant anti-IDs were available for assay development to support pharmacokinetic (PK) and immunogenicity studies within 12 weeks from the start of rabbit immunization. Using this novel rapid and efficient in-house approach we have generated a large panel of anti-IDs against a series of 11 therapeutic antibody drugs and successfully applied them to the clinical assay development.

Citing Articles

Generation of canine neutralizing antibodies against canine parvovirus by single B cell antibody technology.

Wang Z, Shi P, Wang S, Lin Z, Wang Z, Zhang C Arch Virol. 2024; 169(11):225.

PMID: 39424661 DOI: 10.1007/s00705-024-06156-7.


Structure- and machine learning-guided engineering demonstrate that a non-canonical disulfide in an anti-PD-1 rabbit antibody does not impede antibody developability.

Liang W, Xi H, Sun D, DAscenzo L, Zarzar J, Stephens N MAbs. 2024; 16(1):2309685.

PMID: 38356181 PMC: 10877986. DOI: 10.1080/19420862.2024.2309685.


Successful Development of Nonclinical Anti-Drug Antibody Assays to Support Zinpentraxin Alfa Reproductive Toxicology Studies.

Arjomandi A, Siradze K, Cheu M, Davancaze T, Yadav R, Rao G AAPS J. 2024; 26(1):16.

PMID: 38267613 DOI: 10.1208/s12248-024-00891-0.


Novel Selective Quantification of Zinpentraxin Alfa Biotherapeutic in the Presence of Endogenous Isomer in Plasma Samples of Idiopathic Pulmonary Fibrosis Patients Using Immunoaffinity LC-MS.

Li M, Arjomandi A, Sun X, Lu E, Tyagi T, Lin W AAPS J. 2023; 26(1):9.

PMID: 38114736 DOI: 10.1208/s12248-023-00878-3.


Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8.

Sun D, Sun Y, Janezic E, Zhou T, Johnson M, Azumaya C Nat Commun. 2023; 14(1):7940.

PMID: 38040762 PMC: 10692165. DOI: 10.1038/s41467-023-43601-8.


References
1.
LARKIN M, Blackshields G, Brown N, Chenna R, McGettigan P, McWilliam H . Clustal W and Clustal X version 2.0. Bioinformatics. 2007; 23(21):2947-8. DOI: 10.1093/bioinformatics/btm404. View

2.
Huehls A, Coupet T, Sentman C . Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2014; 93(3):290-6. PMC: 4445461. DOI: 10.1038/icb.2014.93. View

3.
DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B . Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003; 20(11):1885-900. DOI: 10.1023/b:pham.0000003390.51761.3d. View

4.
Harth S, Ten Haaf A, Loew C, Frisch C, Knappik A . Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. MAbs. 2018; 11(1):178-190. PMC: 6343800. DOI: 10.1080/19420862.2018.1538723. View

5.
Wranik B, Christensen E, Schaefer G, Jackman J, Vendel A, Eaton D . LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J Biol Chem. 2012; 287(52):43331-9. PMC: 3527920. DOI: 10.1074/jbc.M112.397869. View